You are here

AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.

Company Information
Address
7514 GIRARD AVE STE 301
LA JOLLA, CA 92037-5149
United States


http://www.alspinc.com

Information

UEI: SMP1L5RM3WD1

# of Employees: 3


Ownership Information

HUBZone Owned: Yes

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Administrative Supplement to restore fee funds

    Amount: $623,350.00

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlyi ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  2. Development of protease inhibitor drugs to treat Alzheimer's disease

    Amount: $1,144,770.00

    Not Available

    SBIRPhase II2009Department of Health and Human Services National Institutes of Health
  3. Development of E64d for Alzheimer's disease

    Amount: $1,148,520.00

    Not Available

    SBIRPhase II2009Department of Health and Human Services National Institutes of Health
  4. Development of E64d for Alzheimer's disease

    Amount: $115,137.00

    DESCRIPTION (provided by applicant): There currently is no drug available that stops the progression of Alzheimer's disease (AD). The abnormal accumulation of neurotoxic brain ss-amyloid peptides (A?) ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  5. Development of protease inhibitor drugs to treat Alzheimer's disease

    Amount: $95,089.00

    DESCRIPTION (provided by applicant): There currently is no drug available that stops the progression of Alzheimer's disease (AD). Neurotoxic ?-amyloid peptides (A??) are thought to cause the disease ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  6. Gamma Secretase Assays to Discover Drugs for Alzheimer's

    Amount: $1,541,520.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a long-term, debilitating disorder that causes loss of memory and cognitive functions. There is an urgent need for effective therapeuti ...

    SBIRPhase II2005Department of Health and Human Services National Institutes of Health
  7. Drugs to Elevate Enkephalin as Novel Opiate Analgesics

    Amount: $157,550.00

    DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition that is under-treated because of the dose-limiting side effects of currently used opiate drugs such as morphine. Enkephal ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government